亚洲欧美综合图片高清偷拍|久久久久春色视频|不卡在线观看一区二区三区|久久综合中文字幕|国精产品一区一区三区有av|日本学生妹插逼视频片|av国产专区久久福利导航|国产精品免费性爰视频|亚洲Av免费国产人人操免费|在线激情电影国产

轉(zhuǎn)自雙語君

       12月31日，國務(wù)院聯(lián)防聯(lián)控機制發(fā)布，國藥集團中國生物新冠滅活疫苗已獲得國家藥監(jiān)局批準附條件上市。

       China announced it has granted conditional market approval for its first COVID-19 vaccine during a Thursday news conference.

       The vaccine, developed by State-owned Sinopharm, was approved by China's top drug regulator on Wednesday night, said Chen Shifei, deputy head of the National Medical Products Administration.

       國家藥品監(jiān)督管理局副局長陳時飛稱，國家藥監(jiān)局已于30日附條件批準了國藥集團中國生物北京公司新冠病毒滅活疫苗注冊申請。

       已有數(shù)據(jù)顯示，疫苗保護率為79.34%，實現(xiàn)安全性、有效性、可及性、可負擔(dān)性的統(tǒng)一，達到世界衛(wèi)生組織及國家藥監(jiān)局相關(guān)標(biāo)準要求。后續(xù)，疫苗免疫的持久性和保護效果還需持續(xù)觀察。

       The vaccine is generally safe and has a 79.34 percent efficacy rate according to clinical results released by the company on Wednesday. Strict supervision will continue to be carried out over the vaccine after its approval to ensure its safety and quality, Chen said.

       這一成果來之不易，中國疫苗上市為全球戰(zhàn)勝疫情注入信心，也為疫苗成為全球公共產(chǎn)品提供有力支撐。